SAN CARLOS, Calif.–(BUSINESS WIRE)-–BioCardia, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported filing a second Investigational Device Exemption with the FDA for the CardiAMP Chronic Myocardial Ischemia Trial to treat patients with refractory angina. This second potential indication for CardiAMP investigational cell therapy of […]